October 1, 2007 - BioMerieux, a developer of in vitro diagnostics, announced the launch of VIDAS NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics.
VIDAS NT-proBNP (N-terminal pro-B-type natriuretic peptide), a quantitative marker of heart stress, reportedly provides objective diagnostic information that helps distinguish heart failure from other disease states with similar clinical symptoms, for instance lung diseases or pulmonary embolism. The company says it has the potential to detect early stages of heart failure in the absence of clinically obvious symptoms. In addition, it can be used to assess the prognosis of patients with established heart failure or acute coronary syndrome.
The VIDAS design reportedly makes this assay available 24 hours a day for emergency departments.
For more information: www.bioMerieux.com
June 20, 2024 
